Medicare reimbursement approval for in-house NGS panels / Discontinuation of single-gene orders, Wednesday, June 1st, 2022

Medicare reimbursement approval for in-house NGS panels / Discontinuation of single-gene orders, Wednesday, June 1st, 2022

The Molecular Pathology laboratory is excited to announce CMS reimbursement approval from the Molecular Diagnostic Services Program (MolDX) for the following in-house test offerings:

Z-code	Test	CPT	LAB order code	CMS decision	Effective
Z00BN	Iowa Cancer Mutation Panel with Interpretation	81479	LAB8948	Approved	4/8/2022
Z0024	Tumor Gene RNA Fusion Panel	81445	LAB8956	Approved	3/18/2022
ZB5XC	Lung Gene RNA Fusion Panel	81445	LAB8567	Approved	3/18/2022
ZB52Z	Sarcoma Fusion Panel with Interpretation	81445	LAB8427	Approved	3/18/2022
ZB536	Acute Myelogenous Leukemia Mutation Panel	81450	LAB9075	Approved	9/16/2017

Historically offered single-gene test orders will soon be transitioning to panel orders. Panel orders offer the benefit of obtaining more information for less cost to the patient. Please reference the list below regarding which tests are to be discontinued and the recommended replacement.

Single-Gene Test Orders to be Discontinued	CMS-Approved Test Replacement	LAB order code
BRAF/RAS (BRAF, KRAS, NRAS, HRAS), EGFR, PDGFRA, PIK3CA	Iowa Cancer Mutation Panel with Interpretation	LAB8948
BRAF fusions, FGFR (1, 2, and 3) fusions, NTRK (1, 2, and 3) fusions	Tumor Gene RNA Fusion Panel	LAB8956
EWSR1 fusions, STAT6 fusions, SS18 fusions	Sarcoma Fusion Panel with Interpretation	LAB8427
ASXL1, IDH1/IDH2, EZH2, TP53	Acute Myelogenous Leukemia Mutation Panel	LAB9075

Questions can be directed to Deqin Ma, MD, Molecular Laboratory Director (384-5700, deqin-ma@uiowa.edu) or Sarah Hornberg, Molecular Laboratory Supervisor (384-9870, sarah-hornberg@uiowa.edu).